CellTolerance™ is a unique science-based program designed with physicians and dietitians New data...
Pancreatic cancer remains difficult to diagnose accurately using conventional methods often leading to...
All the resolutions proposed by the Board of Directors were adopted Paris and Boston, June 7, 2024 - 8:00 a.m. CEST - Mauna Kea Technologies...
JV now operational to start selling products in China Paris and Boston, June 6, 2024 – 5:45 p.m. CEST – Mauna Kea Technologies...
Mauna Kea Technologies Winner of “Best New Technology Solution – Oncology” MedTech Breakthrough Award Prestigious...
Paris and Boston, May 21, 2024 - 5:45 p.m. CEST - Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...
AI, pancreatic cancer and food intolerance headline wide range of Cellvizio abstracts at gastroenterology’s largest international...
Paris and Boston, April 30, 2024 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the...
Cellvizio utilization continues to expand globally in established and emerging clinical indications Paris and Boston, April 29, 2024 –...
Full Year 2023 Sales increased +42%1 to €10.5m €1.2m positive full-year operating income +47% growth in Q1 2024 in U.S PPU...
Renewed EIB confidence in Mauna Kea extending support until 2029 Final maturities deferred 4 years to 2028 and 2029 Alignment of debt...
Italy becomes the third country to launch a Cellvizio Center of Excellence following the Metrodora Institute in the U.S. and several other centers...
